XAV-939 No Further a Mystery
Success of the 2nd comparative research were noted by Flinn et al. This is a stage III randomized Intergroup trial evaluating FC regimen compared to FAMP on your own in 278 individuals receiving their to start with chemotherapy program for B-CLL. Dosages of FC agenda had been similar to the 1st exam